Survival prediction and analysis of drug-resistance genes in HER2-positive breast cancer
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study developed a risk model for HER2-positive breast cancer prognosis using 5 key genes. MED1 was identified as a crucial gene in mediating drug resistance, offering a potential therapeutic target.
Area Of Science
- Oncology
- Genomics
- Molecular Biology
Background
- Drug resistance is a major obstacle in treating HER2-positive breast cancer, impacting patient outcomes.
- Existing therapies face limitations due to the development of resistance.
- Identifying predictive markers and resistance mechanisms is crucial for improving treatment strategies.
Purpose Of The Study
- To develop a predictive risk model for patient prognosis in HER2-positive breast cancer.
- To identify key genes involved in mediating drug resistance.
- To explore potential therapeutic targets for overcoming drug resistance.
Main Methods
- Utilized The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases for predictive model construction.
- Constructed a risk model based on 5 identified drug resistance-related genes.
- Performed eccDNA and transcriptome sequencing on drug-sensitive and resistant cancer cells to identify differentially expressed genes (DEGs).
Main Results
- A 5-gene risk model effectively predicted patient survival rates in HER2-positive breast cancer.
- Identified 3 significant DEGs: MED1, MED24, and NMD3, through sequencing.
- MED1 exhibited the most significant upregulation in drug-resistant cells, indicating its critical role.
Conclusions
- The developed risk model can aid in predicting prognosis for HER2-positive breast cancer patients.
- MED1 is a key mediator of drug resistance and a potential therapeutic target.
- Further research into MED1 inhibition could offer new strategies to overcome drug resistance in HER2-positive breast cancer.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...